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B
ile acids have long been known to
facilitatedigestionandabsorptionof
lipidsinthesmallintestineaswellas
regulate cholesterol homeostasis (1,2).
Over the last decade, however, it has be-
come clear that bile acids are not simply
digestive detergents and the primary
route governing cholesterol catabolism.
Bile acids are now recognized as hor-
mones involved in the regulation of vari-
ous metabolic processes (3). Through
activation of various signaling pathways,
bileacidsregulatenotonlytheirownsyn-
thesis and enterohepatic circulation, but
alsotriglyceride,cholesterol,glucose,and
energy homeostasis (2).
Manipulation of bile acid enterohe-
patic circulation by bile acid sequestra-
tionwithnonsystemicallyabsorbedresins
can modulate the processes regulated by
bile acids. Whereas bile acid sequestrants
(BASs)havebeenusedforover40yearsin
the treatment of dyslipidemia (1), more
recent data have emerged that have ex-
panded their role in the treatment of dys-
glycemia in type 2 diabetes (4–9). The
initial data suggesting such an effect were
derivedfromposthocanalysisofaclinical
trialfordyslipidemiathatdeterminedthat
BASs lowered glucose, particularly when
compared with other lipid-lowering
drugs (4). This concept was subsequently
proven in several studies showing that
BASs, such as colesevelam, lower glucose
(5–8).
This review examines recent data ex-
ploring possible mechanisms involved in
regulation of glucose metabolism by bile
acids and the potential impact of disrup-
tion of their enterohepatic circulation on
diabetes. We will also summarize the
available clinical trial data that supported
theregulatoryapprovalofcolesevelamfor
the treatment of hyperglycemia in type 2
diabetes.
TRADITIONAL ROLE OF
BILE ACIDS: DIGESTION,
EXCRETION, AND
AUTOREGULATION— Bile acids
arepotent“digestivesurfactants”thatpro-
mote absorption of lipids (including fat-
soluble vitamins), acting as emulsiﬁers
(1,2).
Bile acids represent the primary path-
way for cholesterol catabolism and ac-
count for 50% of the daily turnover of
cholesterol(1).Thesynthesisofbileacids
occursexclusivelyintheliverinaseriesof
enzymaticreactionsinthehepatocytethat
convert hydrophobic cholesterol into
more water-soluble amphiphatic com-
pounds (2). The production of bile acids
is localized primarily in the perivenous
hepatocytes, that is, the cells surrounding
the central hepatic vein (10).
The immediate products of the bile
acid synthetic pathways are referred to as
primary bile acids. Cholic acid and che-
nodeoxycholic acid are the primary bile
acids formed in humans. The action of
intestinal bacterial ﬂora on primary bile
acids results in the formation of second-
ary bile acid species: deoxycholic and
lithocholic acids, derived from cholic
acid and chenodeoxycholic acid, re-
spectively (2).
The steps leading to formation of pri-
mary bile acids include hydroxylation of
cholesterol, catalyzed by the cytochrome
P450 enzyme cholesterol 7-hydroxylase
(CYP7A1), the ﬁrst and rate-limiting step
of the so-called classic or neutral pathway
of bile acid biosynthesis (1,2,11,12). The
activity of CYP7A1 is subject to complex
modes of control. The conversion of cho-
lesterol to bile acids is primarily deter-
mined by this pathway (2).
Bile acid synthesis can also occur by
an “alternative” or “acidic” pathway,
whichisgovernedbytheenzymeCYP27A1
andconvertsoxysterolstobileacids(1,2).
Unlike CYP7A1, CYP27A1 is not regu-
lated by bile acids (2). It is estimated that
only 6% of bile acid synthesis occurs via
this pathway (13), but data also suggest
that under certain conditions, such as fe-
tal development (14) and chronic liver
disease(13),thispathwaymaycontribute
more signiﬁcantly to bile acid synthesis.
The subsequent conversion of bile acid
intermediates from either the classical or
alternativepathwaystocholicacidorche-
nodeoxycholic acid is governed by
CYP8B1; interaction of these intermedi-
ates with this enzyme determines the
amount of cholic acid versus chenode-
oxycholic acid formed. Hydroxylation via
CYP8B1 results in the formation of the
more hydrophilic cholic acid molecule.
Thus, the cholic acid/chenodeoxycholic
acid ratio determines the overall hydro-
phobicity (and biological properties) of
the bile acids pool (2).
Before their secretion into the bile
canalicular lumen for storage in the gall-
bladder as mixed micelles with phospho-
lipids and cholesterol, primary bile acids
are conjugated with taurine or glycine,
further enhancing their hydrophilicity
(2). Upon ingestion of a meal, gallbladder
contraction releases micellar bile acids
into the intestinal lumen to aid digestion.
Enterohepatic circulation enables 95% of
bile acids to be reabsorbed from the distal
ileumandtransportedbacktothelivervia
the portal circulation. Interestingly, the
perivenous hepatocytes, which account
for the production of bile acids, are not
involved in the reuptake of bile acids; bile
acids are taken up and transported pri-
marily by pericentral hepatocytes that
surround the portal triads, where portal
bloodenterstheliveracinus(15).Thezo-
nation differences accounting for where
bile acids are produced and reenter the
liver are relatively unexplored; thus, the
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observations is unknown at this time (2).
Only 5% of bile acids are not reab-
sorbed and are eliminated in the feces.
This small amount of loss is replenished
via de novo synthesis of bile acids in the
liver (1,2).
The size of the bile acid pool is tightly
regulated within the liver and intestine to
preventcytotoxicaccumulationofbileac-
ids(2).Asthebileacidpoolsizeincreases,
a feedback mechanism, governed by the
interplay of several nuclear receptors, is
activated to inhibit de novo bile acid syn-
thesis. In the liver, the nuclear receptor
living receptor homolog (LRH)-1 acti-
vates gene transcription of the CYP7A1
gene (2). In 1999, bile acids were identi-
ﬁed as the natural ligands for the farne-
soid X receptor (FXR). By binding to the
nuclear receptor FXR, bile acids mediate
control of their own synthesis (16,17).
FXR is thus a “bile acid sensor.” FXR can
be activated by both primary and second-
ary conjugated bile acids, but chenode-
oxycholic acid appears to be the most
potent natural bile acid ligand (16,17).
FXR functions as a biological regulator of
bile acid synthesis through its transcrip-
tional induction of the inhibitory nuclear
receptor SHP (2). In the liver, small het-
erodimer partner (SHP) exerts its inhibi-
tory effect by interacting with LRH-1 and
subsequently repressing CYP7A1 tran-
scription activation by LRH-1 (2). Bile
acids can also inhibit transcription of
CYP7A1 by repressing another nuclear
receptor, hepatocyte nuclear factor
(HNF)-4 (2). Intestinal FXR activation
due to transintestinal bile acid ﬂux after a
meal also induces the expression of ﬁbro-
blastgrowthfactor(FGF)-19,whichisre-
leased by small intestine epithelial cells
and circulates to bind to hepatocyte FGF
receptor4(FGFR4)receptorsthatsignala
reduction in bile acid synthesis via c-Jun
NH2-terminal kinase (JNK) pathway acti-
vation (2). Repression of CYP7A1 results
in decreased synthesis of bile acids from
intrahepatic cholesterol in response to
the daily feeding-fasting cycle. Finally,
emerging evidence suggests that expres-
sion of intestinal bile acid–binding pro-
tein (IBABP), which may be involved in
the shuttling of bile acids from the apical
to basolateral side of enterocytes on reab-
sorption, as well as Na
 taurocholate co-
transporting polypeptide (NTCP), which
uptakes bile acids returning to the liver,
mayalsobeunderpartialFXRcontrol(2).
Thus, FXR activation serves as a critical
modulator of the enterohepatic circula-
tion and de novo synthesis of bile acids to
provide tight regulation of the bile acid
pool (2).
FXR: BEYOND BILE ACID
METABOLISM/HOMEOSTASIS
Lipid metabolism
Whereasmanipulationofbileacidmetab-
olism by bile acid sequestration has been
recognized as a means to control systemic
lipid concentrations since the 1960s, the
underlying molecular mechanisms link-
ing bile acids and lipid metabolism have
only begun to be unraveled over the last
decade. BASs, as well as ileal resection,
which both interrupt the enterohepatic
circulation of bile acids, decrease plasma
total and LDL cholesterol while increas-
inglevelsofHDLcholesterol,apolipopro-
tein (apo)-AI, and triglycerides (18–21).
As a direct consequence of inter-
rupting the return of bile acids to the
liver, CYP7A1 expression becomes de-
repressed, and conversion of cholesterol
into bile acids is stimulated. The deple-
tion of hepatic cholesterol due to in-
creased diversion to bile acid synthesis
leads to increased hepatic LDL receptor
expressiontoharvestcholesterolfromthe
systemic circulation (18). It is this indi-
rect effect on LDL receptor expression
that accounts for the decline in total and
LDLcholesterolproducedbyBASsorileal
resection. However, the increase in HDL
cholesterol and triglyceride levels ob-
served with interruption of the enterohe-
patic circulation of bile acids cannot be
explained by changes in LDL receptor ex-
pression. Animal data have revealed an
independent regulatory role for FXR in
both HDL cholesterol and triglyceride
metabolism. With regard to HDL choles-
terol, FXR represses apoAI expression
(22) and plays a role in HDL particle re-
modeling through induction of phospho-
lipid transfer protein (23). FXR activation
increases clearance of triglycerides by in-
ﬂuencing lipoprotein lipase (LPL) activity
through induction of apoC-II expression
(24) and repression of apoC-III (25) and
by inducing peroxisome proliferator–
activatedreceptor-expression(2)(Fig.1).
Glucose metabolism
The ﬁrst clinical indication that manipu-
lation of the bile acid pool plays a role in
glucose homeostasis resulted from obser-
vations made in a small study conducted
byGargandGrundy(4).Inthisstudy,the
efﬁcacy of 8 g b.i.d. of cholestyramine or
placebowasevaluatedinacrossoverfash-
ionover12weeksin21patientswithtype
2 diabetes stabilized on insulin or gly-
buride, with a baseline LDL cholesterol
3 mmol/l (130 mg/dl) and triglycer-
ides 8 mmol/l (300 mg/dl). Unex-
pectedly, cholestyramine was associated
with a modest improvement in glycemic
control, with mean plasma glucose values
lowered by 13% and a median reduction
in urinary glucose excretion of 0.22 g/day
(P  0.001) and a trend toward lower
glycated hemoglobin concentrations.
These changes occurred without a dosage
adjustment for insulin or glyburide.
These results were later corroborated
with colesevelam and colestimide (5–9).
Similar data on the glucose-lowering ef-
fects of BASs and ileal biliary diversion
have been observed in animal studies as
well (26).
Mechanistic data on the inﬂuence of
bile acids on glucose metabolism have
been mounting. Effects on bile acid pool
composition, FXR-mediated alterations
in hepatic glucose production and intes-
tinal glucose absorption, inﬂuences on
peripheral insulin sensitivity, incretin ef-
fects,andenergyusemayallcontributeto
glucose regulation.
There is evidence that the bile acid
pool size and composition are altered in
animal models of either type 1 or type 2
diabetes (27–29) as well as in humans
with type 1 or 2 diabetes (30,31). The
mechanisms underlying these observa-
tions are unclear, but preliminary evi-
dence suggests a role for insulin (32) and
glucose (33) in modulation of bile acid
synthesis. In the most extensive evalua-
tion of bile acid kinetics to date in age-
andBMI-matchedsubjectswithtype2di-
abetes(31),ahigherrateoftotalbileacids
synthesis, driven by an elevated rate of
cholicacidsynthesisandsubsequentcon-
version to deoxycholic acid, was noted.
Whether this alteration in bile acid pool
composition could play a role in abnor-
mal metabolismindiabetesremainsspecu-
lative, but it is an intriguing possibility.
The type 1 diabetes rat model in-
duced by streptozotocin is associated
with an increased bile acid pool size due
to enhanced synthesis. Hepatic FXR ex-
pression in this model is decreased. As
FXR negatively regulates CYP7A1 activ-
ity, a molecular link between decreased
expression of FXR and increased bile acid
pool size in this model is suggested, since
CYP7A1 mRNA levels are increased. It is
also noteworthy that insulin represses
FXR gene expression, whereas glucose
produces the opposite effect (33). To-
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Study Agents n
Men
(%)
Study
duration
(years)
LDL
cholesterol
reduction
(%)
Patients with
cardiovascular
events (%)
Patients with
coronary
artery disease
progression
(%)*
Patients with
coronary
artery disease
regression
(%)*
BAS monotherapy
Dorr et al. (47) Colestipol 1,149 48 2† 12‡ 4§  ND ND
Placebo 1,129 48 2‡ 9  ND ND
Lipid Research Clinics
Coronary Primary
Prevention Trial (46,48) Cholestyramine 1,906 100 7.4† 20§ 8§¶ ND ND
Placebo 1,900 100 8 10¶ ND ND
National Heart, Lung, and
Blood Institute Type II
Coronary Intervention
Study (20,21) Cholestyramine 59 81 5 26§ ND 32§# 7
Placebo 57 81 5 ND 49# 7
St Thomas’ Atherosclerosis
Regression Study (49) Cholestyramine  diet 24 100 3.3† 36**†† 4§ 12§ ND
Diet 26 100 16**†† 11‡ 15 ND
Usual care 24 100 0 36 46 ND
BAS combination therapy
Cholesterol Lowering
Atherosclerosis Study (50) Colestipol  niacin 94 100 2 43§** 25 10§‡‡ ND
Placebo 94 100 5** 25 22‡‡ ND
Familial Atherosclerosis
Treatment Study (51) Colestipol  niacin 36 100 2.5 32**†† 4§ 25§# 39§#
Colestipol  lovastatin 38 100 46**†† 7§ 21§# 32§#
Usual care 46 100 7** 19 46# 11#
Kane et al. (52) Colestipol  niacin 
lovastatin
40 45 2.2 38§ ND 20§§ 33
Control (plus low-dose
colestipol 14/32 patients)
32 41 11 ND 41§§ 13
Harvard Atherosclerosis
Reversibility Project (53) Stepwise: pravastatin 
niacin  cholestyramine 
gemﬁbrozil
40 90 2.5 38§ 14 33# 13#
Placebo 30 87 3 21 38# 15#
Probucol Quantitative
Regression Swedish Trial (54) Cholestyramine  probucol 138 57 3 3§ 28 ND 0.6, 3  
Cholestyramine  placebo 136 58 8 21 ND 4**, 4  
Armed Forces Regression
Study (55) Cholestyramine  niacin 
gemﬁbrozil
71 90 2.5 22§ 13§ 30¶¶ 52
Placebo 72 94 5 26 50¶¶ 42
Partial ileal bypass
Program on the Surgical
Control of the
Hyperlipidemias (19) Partial ileal bypass 421 91 10 39†† 19§##*** 55§††† 6††
Control 417 91 6†† 30 85 4††
*Includes patients who may have also had regression/progression, except where indicated. †Mean follow-up time reported. ‡Total cholesterol levels reported because LDL
cholesterollevelsnotavailable.§P0.05comparedwithplacebo,usualcare,orcontrol. Percentagerepresentsonlythemenenrolledinthestudy(n	1,094).Differences
were nonsigniﬁcant for women. ¶Only coronary artery disease deaths and nonfatal myocardial infarctions are included. Risk reduction was 19% relative to the incidence of
cardiovascular events in the placebo-treated group. #Deﬁnite or probable progression with no regression or regression with no progression. **P  0.05 compared with
baseline. ††Statistical comparisons not conducted between treatment groups. ‡‡Number represents percentage of patients with new lesions in native vessels. §§Although
not statistically signiﬁcant, there was a strong trend towards favoring active treatment over control.   Numbers represent % increase in femoral artery lumen volume from
baseline and % decrease in roughness of arterial edge. ¶¶Statistical comparisons were only conducted for the percentage of patients who had “controlled” coronary artery
disease (that is, patients who had regression or no change). That comparison (70 vs. 50% for drug therapy vs. placebo) was signiﬁcant (P0.05). ##Only coronary artery
diseasedeathsandnonfatalmyocardialinfarctionsareincluded.***Representsa35%riskreduction.†††Dataon10yearsoffollow-upreported;asigniﬁcantdifferencewas
also observed after 3, 5, and 7 years of follow-up. ND, not determined (values were not determined or not reported). Used with permission from Insull (1).
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is associated with a dysregulation of FXR
expression.
Morerecentworkingeneticallymod-
iﬁed FXR knockout mice has begun to
clarify the role of FXR in glucose metabo-
lism and carbohydrate use. FXR appears
to play a role in modifying carbohy-
drate-induced gene expression as well
as hepatic glucose production during
postprandial and fasting hepatic glucose
utilization, respectively. The precise
mechanisms underlying FXR’s regulation
of glucose metabolism in the liver are
only beginning to be elucidated, but
FXR appears to be involved in the reg-
ulation of a complex array of gluconeo-
genic genes (2), such as those encoding
phosphoenolpyruvate carboxykinase,
fructose-1,6-biphosphatase-1, and glu-
cose-6-phosphatase in vitro (34). FXR
appears to be necessary for preventing
fasting hypoglycemia through mainte-
nance of postprandial hepatic glucose
production and glycogen storage (35).
Moreover, FXR activation inhibits the in-
duction of glucose-responsive genes,
such as L-type pyruvate kinase (L-PK), in
the postprandial state (36). Because bile
acid release is stimulated by meal inges-
tion, it is likely that FXR is activated dur-
ing the enterohepatic recycling of bile
acids(36).Howdiabeticalterationsinthe
bile acid pool affect FXR activation re-
mains to be elucidated and is an area of
active investigation.
Recently,FXRwasfoundtomodulate
glucose absorption in the proximal intes-
tine, since FXR-deﬁcient mice displayed
delayed glucose absorption (37).
Although FXR is primarily localized
in the liver and intestine, it should also be
noted that it is expressed in peripheral
tissues, including adipose tissue, adrenal
glands, and skin (2). Whether minute
concentrations of bile acids escaping the
ﬁrst pass from the liver, which are mea-
surable in plasma, activate peripheral
FXR is unclear. The physiologic role for
peripheral FXR is only beginning to be
understood, but in adipocytes, for exam-
ple, FXR appears to play a role in differ-
entiation and maturation (38). There are
also emerging data to suggest a role in
peripheral insulin sensitivity, which may
beunderpartialregulationbyFXRaswell
(38–40). Nevertheless, these data may
suggest a future role for peripheral FXR
activation in the treatment of insulin re-
sistance and diabetes.
Bile acids may play an additional role
in modulating incretin release through
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protein–coupled cell surface receptor
known as TGR5 (41). This receptor is ex-
pressed in multiple tissues, including the
gallbladder, liver, intestine, brown adi-
pose tissue, central nervous system, and
monocytes/macrophages (41). Litho-
cholic acid appears to be the most potent
bile acid agonist for the receptor (41).
TGR5 biology is incompletely under-
stood, but it may play a role in immune
modulation and hepatocyte protection
from the cytotoxic effects of bile acids
(41).BileacidactivationofTGR5wasalso
recently shown to induce intestinal glu-
cagon-like peptide (GLP)-1 secretion
(42). In type 2 diabetic patients, bile
acidsequestrationwithcolestimidemay
also increase GLP-1 release (43). This
observation has lent support to the in-
volvement of bile acids in mediating the
enteroinsular response to feeding.
Bile acids may also play a role in met-
abolic regulation through modulation of
energyexpenditure.Thiseffectappearsto
be mediated through modulation of ther-
mogenesis. For example, bile acids given
to high fat–fed mice increase energy ex-
penditure in brown adipose tissue, pre-
venting obesity and insulin resistance.
This effect appears to be mediated by in-
duction of the cAMP-dependent thyroid
hormone–activating enzyme type 2 iodo-
thyronine deiodinase (D2); bile acids
increase D2 activity and oxygen consump-
tion in brown adipose tissue, an effect be-
lieved to be mediated by TGR5, not FXR
(44). Support for bile acids mediating en-
ergy expenditure has been provided by a
study in FXR knockout mice. Intrigu-
ingly, when these mice were fasted, they
exhibited accelerated entry into torpor;
thisappearedtobeassociatedwithanim-
paired ability to mobilize energy sub-
strates (glucose and free fatty acids) (45).
These results suggest that bile acids may
also play a complementary role in ther-
mogenesis through FXR-mediated regu-
lation of energy substrate mobilization
and storage (45).
CLINICAL UTILITY OF BILE
ACID SEQUESTRATION:
LEVERAGING THE
METABOLIC EFFECTS OF
BILE ACIDS THROUGH
MANIPULATION OF THE
BILE ACID POOL— As discussed
previously, manipulation of the bile acid
poolthroughbileacidsequestrationtoal-
ter bile acid metabolism has been used
since the 1960s to treat dyslipidemia (1).
BASs deplete the bile acid pool by 40%
and can increase bile acid synthesis over
15-fold (1). This increases diversion of
hepatic cholesterol to bile acid formation,
which indirectly lowers LDL cholesterol
by enhancing hepatic LDL receptor ex-
pression. Lipid alterations produced
throughbileacidsequestrationhavebeen
shown to reduce cardiovascular morbid-
ity and mortality in high-risk males (46)
and have also been shown to induce ath-
erosclerotic plaque regression alone or in
combination with other dyslipidemia
treatments. A summary of these data are
provided in Table 1 (1, used with
permission).
The precise molecular mechanisms
involved in BAS modulation of the bile
acid pool and subsequent effects on glu-
cose metabolism in diabetes are only be-
ginning to be understood and are the
subject of ongoing investigation. In a re-
cently reported study of subjects with
type 2 diabetes, colesevelam-associated
reductionsinA1Candfastingglucosedid
not appear to be related to an improve-
ment in peripheral glucose disposal rate,
but were associated with improvements
in total-body insulin sensitivity, as deter-
minedbyanimprovementintheMatsuda
index. Moreover, data from meal toler-
ance tests showed that colesevelam treat-
ment resulted in reductions in fasting
glucose and systemic glucose exposure
(areaunderthecurveforglucose[AUCg])
withoutsigniﬁcantchangesininsulinlev-
els.Theseresultssuggestthatcolesevelam
may have effects on both insulin sensitiv-
ity and insulin secretion (Schwartz SL et
al. Effect of colesevelam on postprandial
glucose levels in subjects with type 2 dia-
betes mellitus. Abstract. Sixth Annual
WorldCongressontheInsulinResistance
Syndrome, Los Angeles, CA, 25–27 Sep-
tember 2008). In another preliminary
study in db/db diabetic mice, colesevelam
administration improved insulin secre-
toryresponseinthepresenceofhypergly-
cemia. Moreover, microarray analysis of
genes abnormally expressed in the ileum,
liver, skeletal muscle, and adipose tissue
of db/db diabetic mice showed a partial
orcompletenormalizationofexpression
in the db/db diabetic mice relative to con-
trols, particularly in the ileum, after treat-
ment with colesevelam (Forman BM et al.
Colesevelam affects gene expression in
metabolic tissues in db/db mice. Abstract.
American Diabetes Association 68th An-
nual Scientiﬁc Sessions, San Francisco, CA,
6–10 June 2008). Whether the genes dys-
regulated and subsequently normalized
in the db/db diabetic mice reﬂect disrup-
tion of FXR and TGR5 pathways (among
other bile acid–inﬂuenced and non-bile
acid–inﬂuenced pathways) requires fur-
ther study.
It is possible that alterations in bile
acid pool composition produced by BASs
may be involved in the effects observed
with colesevelam on gene regulation and
metabolismdescribedabove.Thebinding
characteristics of a given BAS may have
long-termeffectsonthebileacidspoolby
selectively depleting certain bile acid spe-
cies through fecal elimination, resulting
in an altered ratio of bile acid species in
the pool (56). Preliminary animal data
suggest that alteration of the bile acids
pool can induce profound alterations in
bile acid synthesis, which in turn may
modulate multiple metabolic processes.
In a study of CYP8B1 knockout mice,
changingthecompositionofthebileacids
pool by preventing the generation of
cholic acid resulted in numerous alter-
ations in bile acid metabolism that in-
cluded a striking elevation in CYP7A1
expression and reduced SHP expression,
but no alteration in expression of the bile
salt export protein (57). Conventional
BASs (cholestyramine and colestipol)
have been shown to markedly alter the
composition of bile. For example, cho-
lestyramine preferentially binds the more
hydrophobicbileacidschenodeoxycholic
acid and deoxycholic acid over the more
hydrophilic cholic acid and, therefore,
over time causes a shift in the bile acids
pool to one that is depleted in chenode-
oxycholic acid and deoxycholic acid and
enriched in cholic acid (56). The altered
bile acid ratio also affects the relative de-
gree of hydrophilicity of the bile acid
pool; cholic acid enrichment results in a
more hydrophilic bile acid pool. In addi-
tion to binding chenodeoxycholic acid
and deoxycholic acid, colesevelam differs
from cholestyramine and colestipol in
that it binds cholic acid more effectively
(58). Thus, the bile composition pro-
duced by colesevelam may differ from
ﬁrst-generation BASs, such as cholestyra-
mine. The impact of bile acid seques-
tration on further modiﬁcation (or
normalization) of bile acid pool composi-
tion is currently under investigation (29).
Based on the preliminary observa-
tions of Garg and Grundy (4), BASs
havealsobeendiscoveredtohaveutility
in the treatment of type 2 diabetes;
colesevelam speciﬁcally received a la-
beled indication as adjunctive treat-
ment of this condition in 2008. In
Bile acid and metabolic regulation
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on lipid metabolism, colesevelam also
produced consistent modest incremental
reductions in A1C of up to 0.8% in addi-
tion to LDL cholesterol reductions of up
to17%whengiventotype2diabeticsub-
jects inadequately controlled on stable
regimens of metformin, sulfonylureas, or
insulin (6–8). Reductions in A1C result-
ing from the addition of colesevelam are
similar to changes observed with other
adjunctive antidiabetic therapies in sub-
jects with comparable baseline A1C val-
uesof8–9%,withtheaddedadvantageof
a neutral effect on weight. Side effects
across the pivotal trials were mild and in-
cludedconstipation,nausea,anddyspep-
sia. A detailed summary of these data are
provided in Table 2. Another BAS, co-
lestimide, has also demonstrated effects
on glucose metabolism in an animal
modelofdiet-inducedobesityandinsulin
resistance, suggesting that BASs might
also ﬁnd clinical application in the treat-
ment of metabolic syndrome or pre-
diabetes (60). This represents a potentially
attractivetherapeuticroleforthesedrugs,
considering that they are not systemi-
cally absorbed and have a good safety
record, which may be attractive for
long-term preventive use.
CONCLUSIONS — Knowledge of
bile acid physiology has dramatically
evolved from the concept of digestive de-
tergents to an elegant story of bile acid
functioning as hormones involved in the
modulation of a variety of metabolic pro-
cesses. Manipulation of bile acids compo-
sition and pool size through bile acid
sequestration takes advantage of this
physiology and has found clinical appli-
cation for dyslipidemia and, more re-
cently, type 2 diabetes. Further research
will continue to reﬁne our knowledge of
bileacidphysiologyandwillcontributeto
potential additional therapeutic applica-
tions for these complex molecules.
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